- Phase III data highlight the benefits of ACTEMRA for rheumatoid arthritis -
NUTLEY, N.J., Oct. 20 /PRNewswire/ -- Roche today announced that a total of 15 abstracts involving its investigational rheumatoid arthritis (RA) treatment ACTEMRA(R) (tocilizumab) have been accepted for presentation at the 2008 American College of Rheumatology (ACR) Annual Scientific Meeting, which will take place October 24-29 in San Francisco. These studies evaluate ACTEMRA, a novel treatment targeting interleukin-6 (IL-6) receptors, in patients with moderately to severely active RA.
Platform Presentations/Poster Sessions
-- October 27, 2:45 pm - 3:00 pm PDT, Room 307 [Oral Presentation during
the RA Treatment: Biologic Efficacy RCT's session],
"Tocilizumab Rapidly and Significantly Improves Outcomes in
Patients with Rheumatoid Arthritis Who Have Inadequate Response to TNF
Antagonists" (Presenter: Paul Emery, M.D.)
-- October 27, 3:00 pm - 3:15 pm PDT, Room 307 [Oral Presentation during
the RA Treatment: Biologic Efficacy RCT's session], "The
AMBITION Study: Superiority of Tocilizumab vs. Methotrexate Monotherapy
in Patients with Rheumatoid Arthritis" (Presenter: Graeme Jones,
-- October 28, 3:15 pm - 3:30 pm PDT, Room 307 [Oral Presentation during
the ACR Business Meeting and Late-Breaking Abstracts session],
"Tocilizumab Inhibits Structural Joint Damage in RA Patients with
an Inadequate Response to Methotrexate: The LITHE Study"
(Presenter: Joel M. Kremer, M.D.)
-- There are 12 additional posters and abstracts highlighting results from
the extensive multi-national ACTEMRA clinical development program, which
included more than 4,000 patients in 41 countries, including the U.S.
About ACTEMRA (tocilizumab)
ACTEMRA is the first humanized interleukin-6 (IL-6) receptor-inhibiting
Copyright©2008 PR Newswire.
All rights reserved